Corcept Therapeutics launches first product, Korlym
This article was originally published in Scrip
Executive Summary
Corcept Therapeutics has launched its first drug product, the Cushing's syndrome treatment, Korlym (mifepristone 300mg tablets) in the US, following its approval there in February (scripintelligence.com, 20 February 2012). Its wholesale acquisition cost is $0.62 per milligram, making a price for each daily 300mg pill of $186, and the company has launched a financial assistance and patient support programme for patients.